at Ferring, we define ourselves with a single word.
the health of people comes first
We research, develop, manufacture and market products that work on the body’s own terms to help health care providers combat a wide range of diseases and medical conditions.
@FerringUSA on TwitterToday, positive data were presented from a Phase 3 trial evaluating a gene therapy to treat patients with BCG unresponsive #NMIBC. Learn more: re.ferring.com/2LryMB8
Public Policy Statement:
Proposed Legislation to Improve Price Transparency and Better Serve the Patient, the Taxpayer and the Physician.
WASHINGTON D.C. December 5, 2019 – FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC).
Find out what’s new at Ferring Pharmaceuticals.
View More Press Releases >
passionate people come first to Ferring
What kind of people succeed at Ferring? People who are smart. Curious. Ambitious. People who want to do well. And do good.
Carers. Sharers. Darers.